Company Profile
Kymera Stock Price, News & Analysis
- Ticker:
- KYMR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
106.41 USD (+0.88%)
Close
Last updated: August 6, 2026
5.86B USD
Market cap
Why the stock is moving
The latest company update was “Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update”. KYMR changed 1.04% and closed at $105.48 on Aug 5, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Targeted Protein Degradation
Kymera Therapeutics develops oral small-molecule degraders that recruit the cell’s protein-disposal machinery to remove disease-causing targets. The platform is intended to address proteins and pathways that are difficult to inhibit with conventional drugs.
KT-621
KT-621 is a once-daily oral degrader of STAT6, a transcription factor central to IL-4 and IL-13 signaling in type 2 inflammation. Parallel Phase 2b trials are evaluating the candidate in atopic dermatitis and asthma.
KT-579
KT-579 is an oral degrader of IRF5, a genetically validated regulator of innate and adaptive immune signaling. The candidate is in a first-in-human Phase 1 trial and may have applications across autoimmune diseases including lupus and inflammatory bowel disease.
Partnered and Emerging Programs
Gilead has licensed KT-200, a CDK2 molecular-glue degrader being prepared for IND-enabling development. Kymera is also advancing additional first-in-class degrader candidates toward clinical entry.
Future catalysts
Phase 1 healthy-volunteer data for KT-579 expected in the second half of 2026.
Completion of enrollment in the BROADEN2 Phase 2b atopic-dermatitis trial expected in 2026, with data by mid-2027.
Data from the BREADTH Phase 2b asthma trial expected in late 2027.
IND filing for Gilead-partnered KT-200 planned in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Kymera (KYMR)?
Kymera (KYMR) most recently closed at 106.41 USD, a +0.88% move versus the previous session.
What is the market cap of Kymera (KYMR)?
Kymera currently has a market capitalization of 5.86B USD on BioPharmSignal.
What does Kymera do?
Targeted Protein Degradation Kymera Therapeutics develops oral small-molecule degraders that recruit the cell’s protein-disposal machinery to remove disease-causing targets. The platform is intended to address proteins and pathways that are difficult to inhibit with conventional drugs. KT-621 KT-621 is a once-daily oral degrader of STAT6, a transcription...
On which exchange is KYMR stock listed?
Kymera (KYMR) is associated with NASDAQ, United States, Biopharma.
What is KT-621?
KT-621 KT-621 is a once-daily oral degrader of STAT6, a transcription factor central to IL-4 and IL-13 signaling in type 2 inflammation.
Which conditions is Kymera targeting with KT-621?
Kymera is associated with inflammatory disease, genetic disease based on its company overview and current catalyst commentary.
How does Kymera describe recent progress with KT-621?
Phase 1 healthy-volunteer data for KT-579 expected in the second half of 2026. Completion of enrollment in the BROADEN2 Phase 2b atopic-dermatitis trial expected in 2026, with data by mid-2027. Data from the BREADTH Phase 2b asthma trial expected in late 2027. IND filing for Gilead-partnered KT-200 planned in 2027.
What is IL-4?
KT-621 KT-621 is a once-daily oral degrader of STAT6, a transcription factor central to IL-4 and IL-13 signaling in type 2 inflammation.